TY - JOUR
T1 - Safety and efficacy of transcatheter edge-to-edge repair (TEER) in patients with history of cancer
AU - Khan, Sahoor
AU - Dani, Sourbha S.
AU - Hermann, Joerg
AU - Neilan, Tomas G.
AU - Lenihan, Daniel J.
AU - Fradley, Michael
AU - Parikh, Rohan
AU - Khan, Saafi
AU - Deswal, Anita
AU - Liu, Jennifer
AU - Barac, Ana
AU - Labib, Sherif
AU - Majithia, Arjun
AU - Nohria, Anju
AU - Baron, Suzanne J.
AU - Ganatra, Sarju
N1 - Publisher Copyright:
© 2022 The Author(s)
PY - 2023/2
Y1 - 2023/2
N2 - Background: Surgical therapy has been a long-standing option for valvular heart disease, in patients with history of cancer, it carries an increased risk of complications. Objectives: Transcatheter edge-to-edge repair (TEER) for mitral regurgitation, represents a less invasive option. However, patients with history of cancer have generally been excluded from trials. Methods: A retrospective cohort analysis was performed on de-identified, aggregate patient data from the TriNetX research network. Patients 18 ≥ years of age, who had undergone TEER between January 1, 2013 and May 19, 2021, were identified using the CPT codes and divided into two cohorts based on a history of cancer. Subgroup analysis was performed based on history of systemic antineoplastic therapy. Odds ratio and log-rank test were used to compare the outcomes over 1 and 12-months. Results: In matched cohorts (503 patients in each, mean age 77.7 years, men 55 vs 58 %, white 84 vs 87 % in non-cancer and cancer cohorts respectively), the risk of heart failure exacerbation, all-cause mortality and all-cause hospitalizations were similar at 1 and 12 months among patients undergoing TEER. Risk of major complications (ischemic stroke, blood product transfusion and cardiac tamponade) were also similar. In the cancer cohort, hematologic/lymphoid malignancies were the most common (28.0 %) and 12.5 % patients had a history of metastatic cancer. There was no significant difference in heart failure exacerbation or all-cause mortality based on history of systemic antineoplastic therapy. Conclusions: Overall outcomes following TEER are similar in patients with a history of cancer and should be considered in selected patients in this population.
AB - Background: Surgical therapy has been a long-standing option for valvular heart disease, in patients with history of cancer, it carries an increased risk of complications. Objectives: Transcatheter edge-to-edge repair (TEER) for mitral regurgitation, represents a less invasive option. However, patients with history of cancer have generally been excluded from trials. Methods: A retrospective cohort analysis was performed on de-identified, aggregate patient data from the TriNetX research network. Patients 18 ≥ years of age, who had undergone TEER between January 1, 2013 and May 19, 2021, were identified using the CPT codes and divided into two cohorts based on a history of cancer. Subgroup analysis was performed based on history of systemic antineoplastic therapy. Odds ratio and log-rank test were used to compare the outcomes over 1 and 12-months. Results: In matched cohorts (503 patients in each, mean age 77.7 years, men 55 vs 58 %, white 84 vs 87 % in non-cancer and cancer cohorts respectively), the risk of heart failure exacerbation, all-cause mortality and all-cause hospitalizations were similar at 1 and 12 months among patients undergoing TEER. Risk of major complications (ischemic stroke, blood product transfusion and cardiac tamponade) were also similar. In the cancer cohort, hematologic/lymphoid malignancies were the most common (28.0 %) and 12.5 % patients had a history of metastatic cancer. There was no significant difference in heart failure exacerbation or all-cause mortality based on history of systemic antineoplastic therapy. Conclusions: Overall outcomes following TEER are similar in patients with a history of cancer and should be considered in selected patients in this population.
KW - Antineoplastic therapy
KW - Cancer
KW - Mitral regurgitation
KW - TEER
KW - Trans catheter edge-to-edge repair
UR - http://www.scopus.com/inward/record.url?scp=85145701816&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145701816&partnerID=8YFLogxK
U2 - 10.1016/j.ijcha.2022.101165
DO - 10.1016/j.ijcha.2022.101165
M3 - Article
C2 - 36820391
AN - SCOPUS:85145701816
SN - 2352-9067
VL - 44
JO - IJC Heart and Vasculature
JF - IJC Heart and Vasculature
M1 - 101165
ER -